Literature DB >> 27664282

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

Jocelyn Y Ang1, Nahed Abdel-Haq2, Frank Zhu2, Abrar K Thabit3, David P Nicolau4, Michael J Satlin5, David van Duin6.   

Abstract

We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR) Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by β-lactam allergy. Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27664282      PMCID： PMC5038228          DOI： 10.1128/AAC.00705-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

Authors:  Arnold Louie; Weiguo Liu; Michael VanGuilder; Michael N Neely; Alan Schumitzky; Roger Jelliffe; Steven Fikes; Stephanie Kurhanewicz; Nichole Robbins; David Brown; Dodge Baluya; George L Drusano
Journal:  J Infect Dis       Date:  2014-10-31       Impact factor: 5.226

2.  Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

Authors:  Thomas P Lodise; Ben Lomaestro; George L Drusano
Journal:  Clin Infect Dis       Date:  2007-01-02       Impact factor: 9.079

3.  Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Authors:  Joseph L Kuti; Rebecca S Pettit; Natalie Neu; Jeffrey J Cies; Craig Lapin; Marianne S Muhlebach; Kimberly J Novak; Sean T Nguyen; Lisa Saiman; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2015-05-01       Impact factor: 2.803

Review 4.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

5.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

6.  Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.

Authors:  L Zamorano; C Juan; A Fernández-Olmos; Y Ge; R Cantón; A Oliver
Journal:  Clin Microbiol Infect       Date:  2010-09       Impact factor: 8.067

Review 7.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

Review 8.  Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.

Authors:  D J Touw
Journal:  Pharm World Sci       Date:  1998-08

9.  Mucoid Pseudomonas in cystic fibrosis.

Authors:  Bobbi Pritt; Linda O'Brien; Washington Winn
Journal:  Am J Clin Pathol       Date:  2007-07       Impact factor: 2.493

Review 10.  Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.

Authors:  Mai-Chi Hong; Donald I Hsu; Mark Bounthavong
Journal:  Infect Drug Resist       Date:  2013-11-29       Impact factor: 4.003
View more
  9 in total

Review 1.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic Fibrosis.

Authors:  Justin E Ideozu; Xi Zhang; Amy Pan; Zainub Ashrafi; Katherine J Woods; Martin J Hessner; Pippa Simpson; Hara Levy
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

3.  Characterization and Genomic Analyses of Pseudomonas aeruginosa Podovirus TC6: Establishment of Genus Pa11virus.

Authors:  Chaofei Tang; Chuanjiang Deng; Yi Zhang; Cong Xiao; Jing Wang; Xiancai Rao; Fuquan Hu; Shuguang Lu
Journal:  Front Microbiol       Date:  2018-10-25       Impact factor: 5.640

4.  Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Pseudomonas aeruginosa Isolated From Cystic Fibrosis Patients.

Authors:  Natalia Molchanova; Hengzhuang Wang; Paul R Hansen; Niels Høiby; Hanne M Nielsen; Henrik Franzyk
Journal:  Front Microbiol       Date:  2019-02-20       Impact factor: 5.640

Review 5.  Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data.

Authors:  Silvia Garazzino; Elena Altieri; Erika Silvestro; Giulia Pruccoli; Carlo Scolfaro; Elisabetta Bignamini
Journal:  Front Pediatr       Date:  2020-05-05       Impact factor: 3.418

6.  Nosocomial Chronic Osteomyelitis of the Tibia in an Otherwise Healthy Adolescent: A Case Report.

Authors:  Walter Dehority; Selina Silva; Martha Muller
Journal:  J Orthop Case Rep       Date:  2019

7.  A Rapid and Sensitive Detection Method for Pseudomonas aeruginosa Using Visualized Recombinase Polymerase Amplification and Lateral Flow Strip Technology.

Authors:  Haitao Yang; Yan Wang; Qiankun Yang; Hui Fan; Lei Wang; Tianmeng Zhang; Zhixing Li; Gang Liu; Panpan Zhao; Huahua Wu; Jingquan Dong; Wei Liang
Journal:  Front Cell Infect Microbiol       Date:  2021-09-14       Impact factor: 5.293

Review 8.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24

9.  Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.

Authors:  Emil Lesho; Erik Snesrud; Yoon Kwak; Ana Ong; Rosslyn Maybank; Maryrose Laguio-Vila; Ann R Falsey; Mary Hinkle
Journal:  Antimicrob Resist Infect Control       Date:  2017-08-29       Impact factor: 4.887
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.